XML 45 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment and Geographic Area Information
 12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Segment and Geographic Area Information Segment and Geographic Area Information
AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. This operating structure enables the Chief Executive Officer, as chief operating decision maker (CODM), to allocate resources and assess business performance on a global basis in order to achieve established long-term strategic goals. Consistent with this structure, a global research and development and supply chain organization is responsible for the discovery, manufacturing and supply of products. Commercial efforts that coordinate the marketing, sales and distribution of these products are organized by geographic region or therapeutic area. All of these activities are supported by a global corporate administrative staff. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance, allocating resources and planning and forecasting future periods.
Substantially all of AbbVie's pharmaceutical product net revenues in the United States are to three wholesalers. Outside the United States, products are sold primarily to health care providers or through distributors, depending on the market served. The following tables detail AbbVie's worldwide net revenues:
years ended December 31 (in millions)202320222021
Immunology
HumiraUnited States$12,160 $18,619 $17,330 
International2,244 2,618 3,364 
Total$14,404 $21,237 $20,694 
SkyriziUnited States$6,753 $4,484 $2,486 
International1,010 681 453 
Total$7,763 $5,165 $2,939 
RinvoqUnited States$2,824 $1,794 $1,271 
International1,145 728 380 
Total$3,969 $2,522 $1,651 
Oncology
ImbruvicaUnited States$2,665 $3,426 $4,321 
Collaboration revenues931 1,142 1,087 
Total$3,596 $4,568 $5,408 
VenclextaUnited States$1,087 $1,009 $934 
International1,201 1,000 886 
Total$2,288 $2,009 $1,820 
EpkinlyCollaboration Revenues$28 $— $— 
International
3 — — 
Total
$31 $— $— 
Aesthetics
Botox Cosmetic
United States$1,670 $1,654 $1,424 
International1,012 961 808 
Total$2,682 $2,615 $2,232 
Juvederm Collection
United States$519 $548 $658 
International859 880 877 
Total$1,378 $1,428 $1,535 
Other Aesthetics
United States$1,060 $1,122 $1,268 
International174 168 198 
Total$1,234 $1,290 $1,466 
Neuroscience
Botox Therapeutic
United States$2,476 $2,255 $2,012 
International515 464 439 
Total$2,991 $2,719 $2,451 
Vraylar
United States$2,755 $2,037 $1,728 
International4 1 — 
Total$2,759 $2,038 $1,728 
DuodopaUnited States$97 $95 $102 
International371 363 409 
Total$468 $458 $511 
Ubrelvy
United States$803 $680 $552 
International
12 — — 
Total
$815 $680 $552 
QuliptaUnited States$405 $158 $— 
International3 — — 
Total$408 $158 $— 
years ended December 31 (in millions)202320222021
Other Neuroscience
United States$254 $456 $667 
International22 19 18 
Total$276 $475 $685 
Eye Care
OzurdexUnited States$143 $139 $130 
International329 289 288 
Total$472 $428 $418 
Lumigan/Ganfort
United States$173 $242 $273 
International259 272 306 
Total$432 $514 $579 
Alphagan/Combigan
United States$121 $202 $373 
International151 144 156 
Total$272 $346 $529 
Restasis
United States$382 $621 $1,234 
International54 45 56 
Total$436 $666 $1,290 
Other Eye Care
United States$433 $399 $393 
International370 348 358 
Total$803 $747 $751 
Other Key Products
MavyretUnited States$659 $755 $754 
International771 786 956 
Total$1,430 $1,541 $1,710 
CreonUnited States$1,268 $1,278 $1,191 
Linzess/Constella
United States$1,073 $1,003 $1,006 
International35 32 32 
Total$1,108 $1,035 $1,038 
All other$3,035 $4,137 $5,019 
Total net revenues$54,318 $58,054 $56,197 
Net revenues to external customers by geographic area, based on product shipment destination, were as follows:
years ended December 31 (in millions)202320222021
United States$41,883 $45,713 $43,510 
Germany1,266 1,340 1,223 
Canada1,076 1,159 1,397 
Japan1,008 956 1,090 
China950 912 857 
France780 787 936 
Spain501 506 519 
Italy484 444 506 
Australia472 508 533 
Brazil439 430 368 
United Kingdom417 462 497 
All other countries5,042 4,837 4,761 
Total net revenues$54,318 $58,054 $56,197 
Long-lived assets, primarily net property and equipment, by geographic area were as follows:
as of December 31 (in millions)20232022
United States and Puerto Rico$3,139 $3,243 
Europe1,433 1,369 
All other417 323 
Total long-lived assets$4,989 $4,935